|
Title
|
|
|
|
Phase II study on gemcitabine in recurrent and/or metastatic adenoid cystic carcinoma of the head and neck (EORTC 24982)
| |
|
Author
|
|
|
|
| |
|
Abstract
|
|
|
|
| Background This phase II study was conducted to determine the antitumour activity of gemcitabine in adenoid cystic carcinoma (ACC). Patients and methods Patients with progressive and/or symptomatic, recurrent and/or metastatic ACC were treated with gemcitabine 1250 mg/m2 intravenous (i.v.) on days 1 and 8 of each 21-day cycle. Each cycle was repeated every 3 weeks in the absence of disease progression for a minimum of four cycles and a maximum of 12 cycles. Results Among 21 ACC patients, there were no objective responses. Eleven patients had a stable disease, of which ten patients for more than 6 months, and eight had a progressive disease after 4 cycles. Gemcitabine was well tolerated by most patients. Conclusion We conclude that gemcitabine is not an active drug in ACC. |
| |
|
Language
|
|
|
|
English
| |
|
Source (journal)
|
|
|
|
European journal of cancer. - Oxford, 1990, currens
| |
|
Publication
|
|
|
|
Oxford
:
2008
| |
|
ISSN
|
|
|
|
0959-8049
[print]
1879-0852
[online]
| |
|
DOI
|
|
|
|
10.1016/J.EJCA.2008.08.014
| |
|
Volume/pages
|
|
|
|
44
:17
(2008)
, p. 2542-2545
| |
|
ISI
|
|
|
|
000261562700009
| |
|
Full text (Publisher's DOI)
|
|
|
|
| |
|